Choosing GLP-1 receptor agonists or DPP-4 inhibitors: Weighing the clinical trial evidence

Clinical Diabetes

Volumn 30, Issue 1, 2012, Pages 3-12

  Reid, Timothy ^a  

^a Mercy Diabetes Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; TRIACYLGLYCEROL;

ACUTE PANCREATITIS; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; SYSTOLIC BLOOD PRESSURE;

EID: 84855905976     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.30.1.3     Document Type: Article

References (42)

1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203, 2009
2. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15:540-559, 2009
3. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: AACE/ ACE diabetes algorithm for glycemic control, 2009 [article online]. Available from https://www.aace.com/sites/default/fles/GlycemicControlAlgorithm.pdf. Accessed 17 November 2011
4. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47, 2009
5. Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J: Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 33:1300-1303, 2010
6. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L: Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24:2943-2952, 2008
7. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375:1447-1456, 2010
8. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M: One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 65:397-407, 2011
9. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C: Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33:1509-1515, 2010
10. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I: Effcacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 26:540-549, 2010
11. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG: Effcacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30:1448-1460, 2008
12. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481, 2009
13. Scott R, Wu M, Sanchez M, Stein P: Effcacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as mono-therapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61:171-180, 2007
14. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100, 2005
15. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR: Effcacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90, 2009
16. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G: Effcacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638-2643, 2006
17. DeFronzo RA, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S, Chen RS: The effcacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 32:1649-1655, 2009
18. Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M: The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 9:317-326, 2007
19. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8:436-447, 2006
20. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L: Effcacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32:1224-1230, 2009
21. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP: Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 23:1329-1339, 2007
22. Rosenstock J, Sankoh S, List JF: Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 10:376-386, 2008
23. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R: Saxagliptin added to a submaximal dose of sulphonyl-urea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 63:1395-1406, 2009
24. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metfor-min: a non-inferiority study. Diabetologia 50:259-267, 2007
25. Zinman B, Hoogwerf BJ, Duran GS, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG: The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146:477- 485, 2007
26. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R, On behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52:2046-2055, 2009
27. Hollander P, Li J, Allen E, Chen R: Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 94:4810-4819, 2009
28. Amylin Pharmaceuticals: Byetta package insert. San Diego, Calif., Amylin Pharmaceuticals, 28 July 2008
29. Novo Nordisk: Victoza package insert. Princeton, N.J., Novo Nordisk, 2011
30. Noel RA, Braun DK, Patterson RE, Bloomgren GL: Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32:834-838, 2009
31. Boehringer-Ingelheim Pharmaceuticals Tradjenta package insert. Ridgefeld, Conn., Boehringer-Ingelheim Pharmaceuticals, 2011
32. Parks M, Rosebraugh C: Weighing risks and benefts of liraglutide: the FDA's review of a new antidiabetic therapy. N Engl J Med 362:774-777, 2010
33. U.S. Food and Drug Administration: Byetta: NDA approval: supplemental approval, 2009 [article online]. Available from www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf. Accessed 17 November 2011
34. U.S. Food and Drug Administration: Victoza: NDA approval, 2010 [article online]. Available from www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022341s000ltr.pdf. Accessed 17 November 2011
35. U.S. Food and Drug Administration: Januvia: supplement approval, 2010 [article online]. Available from www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021995s010s011s012s014ltr.pdf. Accessed 17 November 2011
36. U.S. Food and Drug Administration: Onglyza: NDA approval, 2009 [article online]. Available from www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022350s000ltr.pdf. Accessed 17 November 2011
37. Bristol-Myers Squibb: Onglyza package insert. Princeton, N.J., Bristol-Myers Squibb, 2009
38. Merck & Co.: Januvia package insert. Whitehouse Station, N.J., Merck & Co., 2010
39. Bjerre KL, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Molck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M: Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473-1486, 2010
40. U.S. Food and Drug Administration: Tradjenta: NDA approval, 2011 [article online]. Available from www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/201280s000ltr.pdf. Accessed 17 November 2011
41. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ: Safety and effcacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 13:65-74, 2011
42. Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle HJ, Dugi KA: Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and effcacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 27:1409-1419, 2010